FIGURE 1.

Boswellin® Super (BSR) inhibits formation of 5-LOX products but elevates the formation of 12/15-LOX products in human MDM. (A) Impact of Boswellin® Super (BSR) on cell viability of human innate immune cells. LDH release of 1 × 10⁶ M1- and M2-MDMs, 5 × 10⁶ neutrophils, and 5 × 10⁸ platelets after treatment with indicated concentration of BSR or AKBA (10 µM). Triton X-100 was used as a positive control (max. LDH release), and % of control was calculated as per the manufacturer´s guidelines, n = 3 separate donors. (B,C) Human M1-or M2-MDMs (10⁶/mL) were pre-incubated with the indicated concentrations of BSR, AKBA (10 µM) or vehicle (0.2% ethanol) for 30 min and then stimulated with 1% SACM for 90 min at 37°C. Formed LM were isolated from the supernatants and analyzed by UPLC-MS/MS. (B) Heatmap showing the fold changes (logarithmic scale) in LM formation for BSR or AKBA versus vehicle-pretreated cells stimulated with 1% SACM, n = 3, separate donors. (C) Data for M1- and M2-MDMs treated with 50 μg/mL BSR or vehicle (veh.), given as pg/10⁶ cells, means ± S.E.M., n = 3, separate donors. For statistical analysis, data were log-transformed, ratio-paired t-test, *p < 0.05, BSR vs. vehicle control.